NeuroPace, Inc. (NPCE)

Market Cap	391.74M
Revenue (ttm)	65.42M
Net Income (ttm)	-32.96M
Shares Out	28.72M
EPS (ttm)	-1.27
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	42,933
Open	14.19
Previous Close	13.90
Day's Range	13.57 - 14.19
52-Week Range	3.80 - 18.15
Beta	2.09
Analysts	Buy
Price Target	17.00 (+24.63%)
Earnings Date	May 8, 2024

About NPCE

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories....

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Apr 22, 2021
• Employees: 171
• Stock Exchange: NASDAQ
• Ticker Symbol: NPCE

Financial Performance

In 2023, NeuroPace's revenue was $65.42 million, an increase of 43.72% compared to the previous year's $45.52 million. Losses were -$32.96 million, -30.00% less than in 2022.

Analyst Forecast

According to 6 analysts, the average rating for NPCE stock is "Buy." The 12-month stock price forecast is $17.0, which is an increase of 24.63% from the latest price.

Price Target

$17.0

(24.63% upside)

Analyst Consensus: Buy